European Union · Record · QUESTION_WRITTEN_PRIORITY
P-9-2024-000499
Duchenne muscular dystrophy: marketing authorization for Translarna as requested by patients and their families
Introduced
14 February 2024
Last action
—
Status
answered
Sponsors
—
Subjects
Discovery layer
Source updated
19 April 2024
Records
Official record P-9-2024-000499 from European Union at European Parliament. Dated 14 February 2024. Status: answered.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
5 official files
Duchenne muscular dystrophy: authorisation for the marketing of Translarna as requested by sufferers and their families
This file cannot be previewed here. Use View or Download.
Duchenne muscular dystrophy: authorisation for the marketing of Translarna as requested by sufferers and their families
QUESTION_WRITTEN_PRIORITY · EN · 20 February 2024
Duchenne muscular dystrophy: authorisation for the marketing of Translarna as requested by sufferers and their families
QUESTION_WRITTEN_PRIORITY · EN · 20 February 2024
Answer
QUESTION_WRITTEN_ANSWER · 19 April 2024
Distrofia muscolare di Duchenne: autorizzazione alla commercializzazione di Translarna come richiesto dai malati e dalle loro famiglie
QUESTION_WRITTEN_PRIORITY · IT · 20 February 2024
Distrofia muscolare di Duchenne: autorizzazione alla commercializzazione di Translarna come richiesto dai malati e dalle loro famiglie
QUESTION_WRITTEN_PRIORITY · IT · 20 February 2024
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.